Murali Muralidhara

Murali Muralidhara has over 20 years of experience in the pharmaceutical industry. Murali began their career in 1998 as a JSPS postdoctoral fellow at Kyoto University. Murali then became a Robert Welch Postdoctoral Associate at Rice University in 2001. In 2004, they were appointed Assistant Professor and Group Leader of Pharmacology/Pharmaceutics at The University of Texas Medical Branch. In 2006, they joined Pfizer as a Principal Scientist and CMC Teams Leader. In 2011, they were appointed Head of Novel Biologics and Vaccines Development at AstraZeneca. In 2016, they became Senior Director, Global Technical Operations & CMC at Ultragenyx Pharmaceutical Inc. In 2018, they were appointed Vice President: Head of Technical Operations & CMC at Acceleron Pharma. In 2020, they joined GSK as US Head: Strategy & Development, Technical R&D. Most recently, in 2021, they were appointed Chief Manufacturing Officer: Global Head of CMC, Manufacturing, SC & IT at RVAC Medicines.

Muralidhara Murali began their educational journey in 1990, when they obtained a Master's degree in Biochemistry from the University of Mysore. Murali continued their studies at the same university, and in 1998, they earned a PhD in Biochemistry/Biophysical Chemistry.